It was a vaccine from Moderna Company and a product of Pfizer / BioNTech cooperation. These positive test signals also mean the hope that 1 billion people worldwide will be immune to the SARS-CoV-2 virus by the end of next year thanks to the vaccine from the two companies.
The COVID-19 vaccine by Pfizer and Moderna gave roughly similar test results, as they use the same technique to activate the body’s immune system.
Last week, Pfizer announced its vaccine was 90% effective in the third phase of human trials. Meanwhile, Moderna’s COVID-19 vaccine was nearly 95% effective in the late stage trial. Moderna’s vaccine prices are more expensive, ranging from $ 32 to $ 37 for a two-shot dose, while Pfizer is expecting a similar dose of $ 20.
However, the big and quite important difference between the two vaccines is storage conditions. Although more expensive, Moderna vaccines have the advantage of being able to be stored at normal refrigerator temperatures of 2 to 8 degrees C for 30 days, if you want to store longer for long distance transport, you need to be minus 20 degrees C in 6 months. How about from production to customers, Pfizer vaccines need to be stored at minus 70 to minus 80 degrees C, which means Moderna says by the end of 2021 they can produce 1 billion doses and the same frame. This time Pfizer / BioNTech could hit the market at 1.3 billion doses.
The number of vaccines of the two companies will not only be for the US market, but also many countries have an agreement to buy these two vaccines as soon as possible.
The whole world is looking forward to the vaccine. Especially when the second, even third wave of COVID-19 is continuing to paralyze activity in many areas.